CSL Behring Medical Expert Portal is a European webpage designed for healthcare professionals (HCPs) who are interested in serious and life-threatening conditions. Register and login to access the information on this webpage and to receive updates when new content becomes available. If you are interested in the relevant content for a specific country, please refer to the CSL Behring affiliate in your country to obtain relevant information. The medical and scientific information provided on this website is for informational purposes only and should not replace professional advice from a healthcare provider in your area. It is important that you always adhere to the regulations and guidelines relevant to your country.

Disclaimer: Due to compliance regulations, not all content of this webpage is intended for UK healthcare practitioners. If you would like to access UK specific materials on this site, please reach out to your local CSL Behring medical representative (medinfo@cslbehring.com) for assistance.

Disclaimer

CSL EXPERT HIVE

Symposia replays

Unlocking the next step in gene therapy for haemophilia: The end of the beginning?

Pathology:

Haemophilia B

EAHAD, 17th Annual Congress, February 6–9, 2024

Watch the full video recording of the CSL Behring symposium held on February 7, 2024.

This symposium was moderated by Jan Astermark (Sweden) and featured discussions with Daan Breederveld (The Netherlands) and Priyanka Raheja (UK), exploring patient and physician perspectives on gene therapy implementation one-year post-European approval of the first gene therapy for haemophilia B.

To open the symposium, Jan presented data illustrating the journey of gene therapy for haemophilia B. The faculty then presented sessions on: the patient experience of gene therapy trials including recommendations to future gene therapy patients, preparation and administration of gene therapy and discussions around how the haemophilia community can work together to implement gene therapy through innovation, persistence and engagement.

Please note that this symposium contains information on specific products and indications. Please refer to Summary of Product Characteristics available on www.ema.europa.eu for detailed information on HEMGENIX®.